These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 29486710)

  • 1. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
    Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
    BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequence-based detection of first-line and second-line drugs resistance-associated mutations in Mycobacterium tuberculosis isolates in Isfahan, Iran.
    Safari M; Moghim S; Salehi M; Jafari R; Nasr Esfahani B
    Infect Genet Evol; 2020 Nov; 85():104468. PubMed ID: 32711076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco.
    Momen G; Aainouss A; Lamaammal A; Chettioui F; Blaghen M; Messoudi M; Belghmi K; Mouslim J; El Mzibri M; El Messaoudi MD; Khyatti M; Chaoui I
    Rev Inst Med Trop Sao Paulo; 2021; 63():e19. PubMed ID: 33787739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
    Kateete DP; Kamulegeya R; Kigozi E; Katabazi FA; Lukoye D; Sebit SI; Abdi H; Arube P; Kasule GW; Musisi K; Dlamini MG; Khumalo D; Joloba ML
    BMC Pulm Med; 2019 Jul; 19(1):124. PubMed ID: 31291943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of drug resistance-associated mutations among clinical multidrug-resistant Mycobacterium tuberculosis isolates from Hebei Province, China.
    Li Q; Wang Y; Li Y; Gao H; Zhang Z; Feng F; Dai E
    J Glob Antimicrob Resist; 2019 Sep; 18():168-176. PubMed ID: 30926465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
    Bakuła Z; Napiórkowska A; Kamiński M; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J; Jagielski T
    J Microbiol Immunol Infect; 2016 Jun; 49(3):439-44. PubMed ID: 26117528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis.
    Habibnia S; Karami-Zarandi M; Zaker S; Ghalavand Z; Doustdar F; Eslami G; Kazemian H
    Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations.
    Rodwell TC; Valafar F; Douglas J; Qian L; Garfein RS; Chawla A; Torres J; Zadorozhny V; Kim MS; Hoshide M; Catanzaro D; Jackson L; Lin G; Desmond E; Rodrigues C; Eisenach K; Victor TC; Ismail N; Crudu V; Gler MT; Catanzaro A
    J Clin Microbiol; 2014 Mar; 52(3):781-9. PubMed ID: 24353002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.
    Chand AB; Basnet A; Maharjan B; Rai G; Joshi YP; Bhatt LR; Sen B; Rai SK
    PLoS One; 2024; 19(5):e0301210. PubMed ID: 38709710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of
    Bablishvili N; Tukvadze N; Shashkina E; Mathema B; Gandhi NR; Blumberg HM; Kempker RR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M/XDR-TB strains isolated in Thailand.
    Sowajassatakul A; Prammananan T; Chaiprasert A; Phunpruch S
    BMC Microbiol; 2014 Jun; 14():165. PubMed ID: 24953243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant
    Varghese B; Al-Hajoj S
    Am J Trop Med Hyg; 2017 May; 96(5):1066-1070. PubMed ID: 28500800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from high prevalence tuberculosis states in Mexico.
    Juarez-Eusebio DM; Munro-Rojas D; Muñiz-Salazar R; Laniado-Laborín R; Martinez-Guarneros JA; Flores-López CA; Zenteno-Cuevas R
    Infect Genet Evol; 2017 Nov; 55():384-391. PubMed ID: 27637930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China.
    Yuan X; Zhang T; Kawakami K; Zhu J; Li H; Lei J; Tu S
    J Clin Microbiol; 2012 Jul; 50(7):2404-13. PubMed ID: 22553245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil.
    Matsui T; Pinhata JMW; Rabello MCDS; Brandão AP; Ferrazoli L; Leão SC; Viana-Niero C; Oliveira RS
    Mem Inst Oswaldo Cruz; 2020; 115():e200055. PubMed ID: 32401997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region.
    Porwal C; Kaushik A; Makkar N; Banavaliker JN; Hanif M; Singla R; Bhatnagar AK; Behera D; Pande JN; Singh UB
    PLoS One; 2013; 8(2):e55299. PubMed ID: 23390524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort.
    Syed RR; Catanzaro DG; Colman RE; Cooney CG; Linger Y; Kukhtin AV; Holmberg RC; Norville R; Crudu V; Ciobanu N; Codreanu A; Seifert M; Hillery N; Chiles P; Catanzaro A; Rodwell TC
    J Clin Microbiol; 2023 Mar; 61(3):e0147822. PubMed ID: 36757183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redefining MDR-TB: Comparison of Mycobacterium tuberculosis clinical isolates from Russia and Taiwan.
    Jou R; Lee WT; Kulagina EV; Weng JY; Isakova AI; Lin WH; Antonova OV; Wu MH; Arslanbaeva LR; Tasi HY; Nosova EY; Zimenkov DV
    Infect Genet Evol; 2019 Aug; 72():141-146. PubMed ID: 30593924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.
    Ei PW; Aung WW; Nyunt WW; Swe TL; Htwe MM; Win SM; Aung ST; Chang CL; Lee HY; Lee JS
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):47-53. PubMed ID: 29297425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
    Chaoui I; Oudghiri A; El Mzibri M
    J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.